Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 4/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.51 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412620 | 1.00 | ALOX12 (0.65) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL12825176 | 1.00 | ALOX12 (0.65) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL13640753 | 0.90 | PTPN1 (0.56) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL2850735 | 0.90 | CYP19A1 (0.54) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL17963719 | 0.89 | PTPN1 (0.57) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL30217542 | 0.89 | PTPN1 (0.57) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL14183128 | 0.88 | PTPN1 (0.52) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL15070036 | 0.87 | ALOX12 (0.60) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| Dihydrobiochanin A SCHEMBL30217535 | 0.87 | ALOX12 (0.67) | ALOX12PTPN1CYP3A4MEN1KMT2A | |
| SCHEMBL678220 | 0.86 | ALOX12 (0.58) | ALOX12PTPN1CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| CN-114957181-A | Method for separating and purifying high-isoflavone compounds in rhizoma polygonati by high-speed counter-current chromatography | 山东省分析测试中心 | 2022-08-30 | — | — | CN | claimed |
| EP-3351258-B1 | A METHOD FOR PRODUCING AN EQUOL- AND ORNITHINE-CONTAINING FERMENTED SOYBEAN HYPOCOTYL MATERIAL | OTSUKA PHARMA CO LTD (JP) | 2021-01-20 | — | — | EP | claimed |
| US-20200206198-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2020-07-02 | — | — | US | claimed |
| EP-3658136-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | Raia, Valeria (IT) | 2020-06-03 | — | — | EP | claimed |
| WO-2019020663-A1 | CFTR CHANNEL ACTIVATOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF GLUTEN SENSITIVITY CONDITIONS | MAIURI LUIGI (IT) | 2019-01-31 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | NOXOPHARM LIMITED (AU) | 2023-01-24 | — | — | US | disclosed |
| CN-114957181-A | Method for separating and purifying high-isoflavone compounds in rhizoma polygonati by high-speed counter-current chromatography | 山东省分析测试中心 | 2022-08-30 | — | — | CN | disclosed |
| US-11229703-B2 | Radiotherapy improvements | NOXOPHARM LIMITED (AU) | 2022-01-25 | — | — | US | disclosed |
| US-20210338576-A1 | CANCER TREATMENT | NOXOPHARM LIMITED (AU) | 2021-11-04 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| WO-2006031008-A1 | NOVEL MICROORGANISM CAPABLE OF METABOLIZING ISOFLAVONE | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2006-03-23 | — | — | WO | disclosed |
| EP-1049451-B1 | USE OF COMPOUNDS FOR PROTECTING SKIN FROM UV INDUCED IMMUNOSUPPRESSION | NOVOGEN RES PTY LTD (AU) | 2005-11-30 | — | — | EP | disclosed |
| WO-2002089757-A3 | USE OF ISOFLAVONES IN COSMETIC OR DERMATOLOGICAL PREPARATIONS | BEIERSDORF AG (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002089757-A2 | USE OF ISOFLAVONES IN COSMETIC OR DERMATOLOGICAL PREPARATIONS | BEIERSDORF AG (DE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1049451-A4 | COMPOSITIONS AND METHOD FOR PROTECTING SKIN FROM UV INDUCED IMMUNOSUPPRESSION AND SKIN DAMAGE | NOVOGEN RES PTY LTD (AU) | 2001-04-11 | — | — | EP | disclosed |
| EP-1049451-A1 | COMPOSITIONS AND METHOD FOR PROTECTING SKIN FROM UV INDUCED IMMUNOSUPPRESSION AND SKIN DAMAGE | Novogen Research Pty. Ltd. (AU) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036050-A1 | COMPOSITIONS AND METHOD FOR PROTECTING SKIN FROM UV INDUCED IMMUNOSUPPRESSION AND SKIN DAMAGE | NOVOGEN RESEARCH PTY. LTD. (AU) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559510-B2 | Isoflavonoid composition with improved pharmacokinetics | SI, CYP51A1, CYP19A1 | ALOX12 445/4885PTPN1 4884/4885CYP3A4 90/4885 |
| US-20210338576-A1 | CANCER TREATMENT | TP53, HIF1AN, HIF1A | ALOX12 1349/4885PTPN1 3563/4885CYP3A4 1459/4885 |
| US-11229703-B2 | Radiotherapy improvements | MRE11, TP53, CHEK2 | ALOX12 3305/4885PTPN1 2246/4885CYP3A4 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.